CervoMed (CRVO)’s Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB)

CervoMed Inc. (NASDAQ:CRVO) earns a place on our top 10 stocks under $5 that could triple.

On March 17, 2026, CervoMed Inc. (NASDAQ:CRVO) announced results for the fourth quarter and full year 2025. The company highlighted advancements in its neflamapimod program for dementia with Lewy bodies (DLB).

CervoMed Inc. (NASDAQ:CRVO) further reported favorable Phase 2b RewinD-LB data at CTAD 2025 while achieving an agreement with the FDA and international authorities on the design of a Phase 3 trial. This trial is expected to commence in the latter part of 2026. With the start of the EXPERTS-ALS investigation and topline findings from Phase 2a trials in ischemic stroke recovery and primary progressive aphasia, the upcoming calendar remains catalyst-heavy.

In terms of finances, CervoMed Inc. (NASDAQ:CRVO) reported $20.9 million in cash as of December 31, 2025, indicating a runway of roughly six months, with R&D expenses of $21.8 million and a net loss of $27.0 million for the year.

A day later, Boobalan Pachaiyappan of Roth Capital reduced the price target on CervoMed Inc. (NASDAQ:CRVO) from $19 to $11 while keeping a “Buy” rating. The analyst noted that results were largely in line with expectations, but the company may need to raise capital on less favorable terms.

CervoMed Inc. (NASDAQ:CRVO) is a clinical-stage biotechnology firm specializing in CNS-targeted therapeutics, namely, neflamapimod, aimed at neurodegenerative conditions such as dementia with Lewy bodies, stroke rehabilitation, and several other cerebral disorders.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.